secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalon GloboCare Corp. (ALBT)
CIK:        0001630212
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001213900-23-033285
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalon GloboCare reports LSM 2022 revenue $14.7M, net income $6.3M; 40% interest acquired Feb 2023
--------------------------------------------------------------------------------

- LSM FY2022: revenue $14.7M, gross profit $8.1M, net income $6.3M, total operating expense $2.4M.
- Avalon acquired 40% of LSM in Feb 2023; profit-sharing arrangement expected to produce significant future cash flow.
- LSM provides broad diagnostic tests (drug testing, toxicology, pharmacogenetics, etc.) and has completed 600K+ tests since inception.
- CEO cites fragmented lab market as roll-up opportunity to leverage LSM infrastructure for synergies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630212/000121390023033285/0001213900-23-033285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630212/000121390023033285/ea177537-8k_avalon.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-033285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer